CO2020004200A2 - Anticuerpo monoclonal anti-il-5rα - Google Patents
Anticuerpo monoclonal anti-il-5rαInfo
- Publication number
- CO2020004200A2 CO2020004200A2 CONC2020/0004200A CO2020004200A CO2020004200A2 CO 2020004200 A2 CO2020004200 A2 CO 2020004200A2 CO 2020004200 A CO2020004200 A CO 2020004200A CO 2020004200 A2 CO2020004200 A2 CO 2020004200A2
- Authority
- CO
- Colombia
- Prior art keywords
- monoclonal antibody
- antibodies
- methods
- relates
- biotechnology
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al campo de la biotecnología y proporciona anticuerpos que se unen específicamente a IL-5Rα. La invención también se refiere a la codificación DNA de dichos anticuerpos, los correspondientes vectores de expresión y a métodos de producción de los mismos, como así también a métodos para tratamiento que usan dichos anticuerpos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017134413A RU2698048C2 (ru) | 2017-10-03 | 2017-10-03 | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
PCT/RU2018/050118 WO2019070164A1 (ru) | 2017-10-03 | 2018-10-02 | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020004200A2 true CO2020004200A2 (es) | 2020-04-24 |
Family
ID=65994565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0004200A CO2020004200A2 (es) | 2017-10-03 | 2020-04-03 | Anticuerpo monoclonal anti-il-5rα |
Country Status (23)
Country | Link |
---|---|
US (1) | US20200291121A1 (es) |
EP (1) | EP3693388A4 (es) |
JP (1) | JP7275117B2 (es) |
KR (1) | KR20200058537A (es) |
CN (1) | CN111788223A (es) |
AR (1) | AR113343A1 (es) |
AU (1) | AU2018346116A1 (es) |
BR (1) | BR112020006795A2 (es) |
CA (1) | CA3078467A1 (es) |
CL (1) | CL2020000920A1 (es) |
CO (1) | CO2020004200A2 (es) |
EA (1) | EA202090864A1 (es) |
EC (1) | ECSP20024551A (es) |
JO (1) | JOP20200106A1 (es) |
MA (1) | MA49607A1 (es) |
MX (1) | MX2020004026A (es) |
PE (1) | PE20210466A1 (es) |
PH (1) | PH12020550218A1 (es) |
RU (1) | RU2698048C2 (es) |
TW (1) | TWI758547B (es) |
UY (1) | UY37914A (es) |
WO (1) | WO2019070164A1 (es) |
ZA (1) | ZA202002044B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220035656A (ko) * | 2020-09-14 | 2022-03-22 | 아주대학교산학협력단 | 인간 IL-5Rα에 결합하는 항체 및 이의 용도 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
JP3472297B2 (ja) | 1989-03-21 | 2003-12-02 | ザ イミューン レスポンス コーポレイション | 特定のt細胞集団の病原性応答により生じる疾患に対するワクチン接種および方法 |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
CA2064077C (en) | 1989-07-19 | 2002-03-12 | Arthur A. Vandenbark | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU690474B2 (en) * | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
FR2783326B1 (fr) * | 1998-09-10 | 2000-12-01 | Immunotech Sa | Procede de detection ou de quantification des basophiles et des eosinophiles |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
DE60138222D1 (de) * | 2000-09-14 | 2009-05-14 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
ATE435239T1 (de) * | 2002-03-29 | 2009-07-15 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
WO2005035583A1 (ja) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Il-5受容体に特異的に結合する抗体組成物 |
US20050226867A1 (en) * | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
SG10201503254TA (en) * | 2007-05-14 | 2015-06-29 | Medimmune Llc | Methods of reducing eosinophil levels |
PT2644698T (pt) * | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
DK3033101T3 (en) * | 2013-08-12 | 2019-04-08 | Astrazeneca Ab | PROCEDURES FOR REDUCING EXACT EXERCISE RATES FOR ASTMA USING BENRALIZUMAB |
JP2016539632A (ja) * | 2013-10-25 | 2016-12-22 | ヌマブ アクチェンゲゼルシャフト | 二重特異性構築物と種々の疾患の治療におけるその使用 |
EP3143045A1 (en) | 2014-05-12 | 2017-03-22 | Numab AG | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
-
2017
- 2017-10-03 RU RU2017134413A patent/RU2698048C2/ru active
-
2018
- 2018-09-28 TW TW107134501A patent/TWI758547B/zh active
- 2018-10-02 JO JOP/2020/0106A patent/JOP20200106A1/ar unknown
- 2018-10-02 KR KR1020207012627A patent/KR20200058537A/ko not_active Application Discontinuation
- 2018-10-02 AU AU2018346116A patent/AU2018346116A1/en active Pending
- 2018-10-02 WO PCT/RU2018/050118 patent/WO2019070164A1/ru unknown
- 2018-10-02 MX MX2020004026A patent/MX2020004026A/es unknown
- 2018-10-02 CN CN201880078306.5A patent/CN111788223A/zh active Pending
- 2018-10-02 JP JP2020519415A patent/JP7275117B2/ja active Active
- 2018-10-02 MA MA49607A patent/MA49607A1/fr unknown
- 2018-10-02 BR BR112020006795-4A patent/BR112020006795A2/pt unknown
- 2018-10-02 US US16/753,488 patent/US20200291121A1/en active Pending
- 2018-10-02 EP EP18864122.9A patent/EP3693388A4/en active Pending
- 2018-10-02 CA CA3078467A patent/CA3078467A1/en active Pending
- 2018-10-02 PE PE2020000514A patent/PE20210466A1/es unknown
- 2018-10-02 EA EA202090864A patent/EA202090864A1/ru unknown
- 2018-10-03 UY UY0001037914A patent/UY37914A/es unknown
- 2018-10-04 AR ARP180102863A patent/AR113343A1/es unknown
-
2020
- 2020-04-03 CL CL2020000920A patent/CL2020000920A1/es unknown
- 2020-04-03 PH PH12020550218A patent/PH12020550218A1/en unknown
- 2020-04-03 CO CONC2020/0004200A patent/CO2020004200A2/es unknown
- 2020-05-04 ZA ZA2020/02044A patent/ZA202002044B/en unknown
- 2020-05-06 EC ECSENADI202024551A patent/ECSP20024551A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA202090864A1 (ru) | 2020-06-29 |
MX2020004026A (es) | 2020-08-13 |
RU2017134413A (ru) | 2019-04-03 |
US20200291121A1 (en) | 2020-09-17 |
WO2019070164A1 (ru) | 2019-04-11 |
RU2017134413A3 (es) | 2019-04-03 |
KR20200058537A (ko) | 2020-05-27 |
RU2698048C2 (ru) | 2019-08-21 |
PE20210466A1 (es) | 2021-03-08 |
CN111788223A (zh) | 2020-10-16 |
ZA202002044B (en) | 2022-08-31 |
AR113343A1 (es) | 2020-04-22 |
JP7275117B2 (ja) | 2023-05-17 |
JOP20200106A1 (ar) | 2020-05-06 |
EP3693388A1 (en) | 2020-08-12 |
JP2021501568A (ja) | 2021-01-21 |
EP3693388A4 (en) | 2021-06-23 |
AU2018346116A1 (en) | 2020-05-14 |
PH12020550218A1 (en) | 2021-02-15 |
MA49607A1 (fr) | 2021-03-31 |
BR112020006795A2 (pt) | 2020-10-06 |
TWI758547B (zh) | 2022-03-21 |
CL2020000920A1 (es) | 2020-10-16 |
TW201922789A (zh) | 2019-06-16 |
UY37914A (es) | 2019-04-30 |
ECSP20024551A (es) | 2020-06-30 |
CA3078467A1 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
CO2019009365A2 (es) | Anticuerpos anti-lag3 | |
CO2017005240A2 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
PE20171764A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 | |
CR20170032A (es) | Moleculas biespecíficas de unión a antígeno activadoras de células t | |
CR20130359A (es) | Anticuerpos del cea | |
GT201400045A (es) | Anticuerpo anti-abtcr | |
NI201700022A (es) | Anticuerpo anti-vasa y métodos de producción y uso de los mismos. | |
CL2020001629A1 (es) | Anticuerpos de unión a hla-a2/wt1. | |
CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
EA201892096A1 (ru) | Нейтрализующие моноклональные антитела к il-25 и их применение | |
CO2020004200A2 (es) | Anticuerpo monoclonal anti-il-5rα | |
CO2018010286A2 (es) | Método para la purificación de proteínas | |
CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 |